Biopharma M&A Heats Up, Rare Diseases Win Three Approvals, Wave Crashes

The BioSpaces podcast episode centers on recent biopharma M&A activities, highlighting significant deals and their implications. Merck's $6.7 billion acquisition of Terns is examined in light of Merck's upcoming loss of exclusivity for Keytruda. Eli Lilly's strategic diversification into sleep disorder drugs with the acquisition of Centessa is also discussed. Additionally, Biogen's purchase of Apellis for $5.6 billion, aimed at bolstering their kidney disease expertise and pipeline, is analyzed, along with the company's recent drug approval and positive trial results. The episode also touches on rare disease drug approvals for Hunter syndrome and LADI, as well as Wave Life Sciences' disappointing weight loss data.